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 42 
ABSTRACT 43 
Osteoarthritis (OA) is characterized by synovitis and synovial fibrosis.  Synoviocytes are 44 
fibroblast-like resident cells of the synovium that are activated by TGF- to proliferate, 45 
migrate and produce extracellular matrix.  Synoviocytes secrete hyaluronan (HA) and 46 
proteoglycan-4 (PRG4).  HA reduced synovial fibrosis in vivo and the Prg4
-/-
 mouse exhibits 47 
synovial hyperplasia.  We investigated the antifibrotic effects of increased intracellular 48 
cAMP in TGF-β stimulated human OA synoviocytes.  TGF-β1 stimulated collagen I 49 
(COL1A1), α-SMA, TIMP-1, PLOD2 expression and procollagen I, α-SMA, HA and PRG4 50 
production, migration and proliferation of OA synoviocytes were measured.  Treatment of 51 
OA synoviocytes with forskolin (10μM) increased intracellular cAMP levels and reduced 52 
TGF-β1 stimulated COL1A1, α-SMA and TIMP-1 expression, with no change in PLOD2 53 
expression.  Forskolin also reduced TGF-1 stimulated procollagen I and α-SMA content, as 54 
well as synoviocyte migration and proliferation.  Forskolin (10μM) increased HA secretion, 55 
PRG4 expression and production.  A cell permeable cAMP analog reduced COL1A1 and α-56 
SMA expression and enhanced HA and PRG4 secretion by OA synoviocytes.  HA and PRG4 57 
reduced α-SMA expression and content and PRG4 reduced COL1A1 expression and 58 
procollagen I content in OA synoviocytes.  Prg4
-/-
 synovium exhibited increased α-SMA, 59 
COL1A1 and TIMP-1 expression as compared to Prg4
+/+
 synovium.  Prg4
-/- 
synoviocytes 60 
demonstrated strong α-SMA and collagen type I staining while these were undetected in 61 
Prg4
+/+
 synoviocytes, and was reduced with PRG4 treatment.  We conclude that increasing 62 
intracellular cAMP levels in synoviocytes mitigates synovial fibrosis through enhanced 63 
production of HA and PRG4, possibly representing a novel approach for treatment of OA 64 
synovial fibrosis.  65 
       66 
Keywords: cAMP, fibrosis, PRG4, HA, Osteoarthritis. 67 
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INTRODUCTION 68 
 69 
Hallmarks of osteoarthritis (OA) include cartilage degeneration, subchondral bone 70 
remodeling, and synovitis (26, 27, 41).  Major abnormalities in the OA synovium include 71 
synovial hyperplasia, inflammatory cell infiltration, angiogenesis and fibrosis (4, 45, 47, 55).  72 
Synovial fibrosis is a common feature in advanced OA that contributes to joint pain and 73 
stiffness (13, 24).  The TGF-1 family and its associated signaling pathways play an essential 74 
role in maintaining homeostasis in healthy joints (52).  However, TGF-1 switches to a 75 
pathologic role in OA joints that drives synovial fibrosis (36).  TGF-1 upregulates the 76 
expression of synovial collagen type 1, tissue inhibitor of metalloproteinase 1 (TIMP-1), and 77 
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2) (35, 36).  The net result is an 78 
increase in collagen I formation, an increase in collagen crosslinks and a reduction in 79 
collagen turnover (35, 36).  80 
 81 
The normal synovium contains two types of intimal cells: type A macrophages and type B 82 
fibroblasts, or synoviocytes (48).  In synoviocytes, TGF-1 induces fibrotic changes 83 
characterized by cell proliferation and collagen type I accumulation (46).  Additionally, TGF-84 
1 promotes the differentiation of OA synoviocytes into a myofibroblast-like phenotype, 85 
characterized by the expression of alpha smooth muscle actin (α-SMA) (28).  Synoviocytes 86 
produce hyaluronan (HA), a glycosaminoglycan synthesized by membrane-bound 87 
hyaluronan synthase (HAS) with three isoforms identified to date (HAS1, HAS2 and HAS3) 88 
(54).  Synoviocytes also produce proteoglycan-4 (PRG4), a heavily glycosylated mucinous 89 
glycoprotein (9, 17).  HA and PRG4 play important roles in joint lubrication (25).  HA and 90 
PRG4 may also play a role in joint fibrosis as HA treatment reduced synovial fibrosis in vivo 91 
and findings in synovial tissues from Prg4
-/-
 mice include increased synovial thickening and 92 
a proliferative capacity for Prg4
-/-
 synoviocytes under basal and cytokine stimulated 93 
conditions (2, 32, 37).   94 
 95 
Cyclic adenosine monophosphate (cAMP) is a pleiotropic intracellular second messenger 96 
generated by adenylyl cyclase (AC) enzymes in response to G-protein coupled receptor 97 
(GPCR) activation (16).  The antifibrotic effect of cAMP has been described in fibroblasts 98 
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from multiple origins and include inhibition of fibroblast proliferation, reduction in fibroblast 99 
migration and reduced synthesis of extracellular matrix components (12, 38, 44, 56).  The 100 
role of cAMP in regulating TGF-1’s fibrotic response in synoviocytes is unknown.  Our aim 101 
was to study the impact of forskolin, an AC activator, on the expression and production of α-102 
SMA, collagen type I, and expression of TIMP-1, PLOD2, HAS isoforms, PRG4 and 103 
production of HA and PRG4 in a model of TGF-β1 stimulated OA synoviocytes.  Given the 104 
potential involvement of HA and PRG4 in synovial fibrosis, we also studied the antifibrotic 105 
effect of HA and PRG4 in human and murine synoviocytes.  We hypothesized that increasing 106 
intracellular cAMP exerts an antifibrotic effect in OA synoviocytes and promotes HA and 107 
PRG4 production. 108 
 109 
MATERIALS AND METHODS 110 
 111 
Ethical approvals: Animal breeding and tissue harvest was approved by the IACUC 112 
committee at Rhode Island Hospital.     113 
 114 
Patient characteristics and experimental approach 115 
OA synoviocytes (500,000 cells per vial; Cell Applications, USA) were isolated from 116 
synovial tissues from de-identified OA patients undergoing knee replacement (n=10; median 117 
age = 63; range: 54 to 69).  Six patients were female.  Five patients were Caucasian, and the 118 
other five were unspecified.  Synoviocytes were received in their second passage.  OA 119 
Synoviocytes were cultured in 75 cm
2
 culture flasks in DMEM media supplemented with 120 
10% FBS and were used between the third and sixth passages to avoid alterations in patterns 121 
of gene expression (10, 30).  Experimental data are represented as the mean  S.D. of 3-6 122 
biological replicates.    123 
 124 
We initially studied cAMP generation in OA synoviocytes using a 0.01 to 10M forskolin 125 
concentration range.  The 10M was selected based on previous studies (21, 50).  Following 126 
confirmation of cAMP accumulation by forskolin, we determined its effect on -SMA, 127 
collagen type I, TIMP-1 and PLOD2 expression in TGF-ß1 stimulated OA synoviocytes.  128 
The antifibrotic effect of intracellular cAMP accumulation in OA synoviocytes was further 129 
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confirmed using a cell permeable cAMP analog, 8-bromo cAMP.   To further appreciate the 130 
antifibrotic effect of forskolin, we evaluated the impact of cAMP generation on HAS isoform 131 
expression and HA production, as well as PRG4 expression and production.  Based on 132 
forskolin’s observed effect on HA and PRG4, we studied the antifibrotic effect of HA and 133 
PRG4 in human OA synoviocytes, murine Prg4
-/- 
synoviocytes as well as fibrosis markers in 134 
the Prg4
-/-
 synovium.  Finally, we studied the efficacy of forskolin in mitigating TGF-1 135 
stimulated OA synoviocyte migration and proliferation.  136 
 137 
cAMP generation in OA synoviocytes by forskolin  138 
 139 
cAMP levels were measured in OA synoviocytes using the cADDis assay (Montana 140 
Molecular, USA).  The assay utilizes a fluorescent cAMP sensor that measures changes in 141 
intracellular cAMP levels.  An increase in intracellular cAMP levels results in a reduction in 142 
green fluorescence.  OA synoviocytes (10,000 cells per well) were cultured overnight in 143 
sterile 96-well clear-bottom black plates in the presence of a recombinant mammalianized 144 
baclovirus expressing the cAMP sensor according to manufacturer’s recommendations.  145 
Subsequently, media supernatants were replaced with Dulbecco’s phosphate-buffered saline 146 
(DPBS; Thermo Fisher Scientific, USA) (200μL per well).  Forskolin (Sigma-Aldrich, USA) 147 
at a final concentration of 0.01, 0.1, 1, and 10μM, vehicle and a positive control were added 148 
and fluorescence intensity using 494/522 nm wavelengths was measured every 30 seconds 149 
over 30 minutes.  Data is presented as the ratio of fluorescence intensity reduction at each 150 
time point to fluorescence intensity at baseline.       151 
 152 
Gene expression studies 153 
 154 
OA synoviocytes (300,000 cells per well) were treated with TGF-1 (1ng/mL; R&D systems, 155 
USA) in serum-free DMEM  forskolin (0.1, 1, or 10μM), 8-bromo cAMP (Sigma Aldrich) 156 
(100 and 500M), human synoviocyte PRG4 (apparent MW 280 kDa as a monomer; 157 
100μg/mL) (18) and/or high molecular weight HA (MW >950 kDa; R&D Systems) (100 158 
μg/mL) for 24 hours followed by RNA extraction, cDNA synthesis and qPCR as previously 159 
described (1).  The cycle threshold (Ct) value of target genes were normalized to the Ct value 160 
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of GAPDH in the same sample, and the relative expression was calculated using the 2
-ΔΔCt
 161 
method (23).  Target genes included α-SMA (ACTA2), collagen type I (COL1A1), TIMP-1, 162 
PLOD2, HAS1, HAS2, HAS3, and PRG4 (primers and probes were obtained from Thermo 163 
Fisher Scientific).  Data are presented as fold expression of target genes in the different 164 
experimental groups compared to untreated controls.  165 
 166 
-SMA and procollagen type I quantitation 167 
 168 
OA synoviocytes were seeded in cell culture dishes (20.8 cm
2
) at 1.0 x 10
6
 cells per dish until 169 
confluence.  OA synoviocytes in serum-free DMEM media (5 ml per dish) were treated with 170 
TGF-1 (1ng/mL) ± forskolin (10µM), PRG4 (100µg/mL) or HA (100µg/mL) for 24 hours.  171 
Cell protein extraction was performed using M-PER reagent supplemented with protease and 172 
phosphatase cocktail inhibitor (Thermo Fisher Scientific) and quantified using micro BCA 173 
assay (Thermo Fisher Scientific).   174 
 175 
Gel electrophoresis was performed using 10% PAGE gels (Bio-Rad) and 10g protein per 176 
well.  Following transfer, membranes were blocked with 5% non-fat dry milk for 2 hours at 177 
room temperature.  Membranes were probed with anti--SMA (1:1,000 dilution; ab5694) 178 
and anti-GAPDH (1:5,000 dilution; ab9485) (Abcam) overnight in tris-buffered saline tween 179 
20 (TBS-T).  Following washing with TBS-T, membranes were incubated with horseradish 180 
peroxidase (HRP)-conjugated anti-rabbit (1:5,000 dilution; ab6721) antibody for 1 hour at 181 
room temperature (Abcam).  Protein bands were developed using Lumigen ECL Ultra 182 
reagent (Lumigen, USA) and visualized using Bio-Rad ChemiDoc XRS+ system (Bio-Rad).  183 
Bands of interest were selected and quantified using Image J software.  The ratio of -SMA 184 
band intensities to corresponding GAPDH band intensities of the different experimental 185 
groups were calculated and normalized to controls.     186 
 187 
Procollagen I content in OA synoviocytes was determined using an ELISA (Abcam and 188 
R&D Systems).  A total of 5 g protein in 100 µL buffer was used in each experimental 189 
group and procollagen I concentrations (pg/mL) were divided by 50 and expressed as 190 
procollagen I protein (pg) per µg protein. 191 
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 192 
Immunocytostaining of -SMA in OA synoviocytes 193 
OA synoviocytes (200,000 cells per well) were cultured on collagen type I-coated 12 mm 194 
glass coverslips for 48 hours in DMEM supplemented with 10% FBS.  Subsequently, cells 195 
were treated with TGF-β1 (1 ng/ml)  forskolin (10μM) for 48 hours in serum-free DMEM.  196 
Synoviocytes were fixed in 10% neutral buffered formalin for 10 min followed by washing 197 
twice with PBS.  Cells were permeabilized for 5 min using 0.01% Triton X100 in PBS and 198 
blocked using 2%BSA for 1 hour at room temperature.  Probing was performed using FITC-199 
conjugated anti -SMA antibody (1:100; ab8211; Abcam) and Alexa Fluor 594 conjugated 200 
anti-alpha tubulin antibody (1:500; ab195889; Abcam) overnight at 4
o
C.  Following washing 201 
with PBS, cells were mounted with DAPI mounting medium (Abcam) for 1 hour and viewed 202 
under a confocal microscope     203 
 204 
HA, PRG4 and HAS1 quantitation  205 
 206 
HA concentrations:  OA synoviocytes (300,000 cells per well) in serum-free DMEM were 207 
treated with TGF-1 (1ng/mL) ± forskolin (10μM) for 24 hours.  Media supernatants were 208 
collected and assayed for HA using a quantitative assay kit (R&D systems).  In a separate set 209 
of experiments, OA synoviocytes (300,000 cells per well) in serum-free DMEM were treated 210 
with TGF-1 (1ng/mL) ± 8-bromo cAMP (100 and 500μM) for 24 hours.  HA concentrations 211 
were determined as described above. 212 
 213 
PRG4 concentrations: OA synoviocytes (20,000 cells per well) were seeded in sterile 96 well 214 
plates for 48 hours followed by treatment with TGF-β1 (1ng/mL) ± forskolin (10μM) for 48 215 
hours.  PRG4 concentrations, normalized to cell density, were determined in media 216 
supernatants as previously described (1).  In a separate set of experiments, OA synoviocytes 217 
(300,000 cells per well) in serum-free DMEM were treated with TGF-1 (1ng/mL) ± 8-218 
bromo cAMP (100 and 500μM) for 24 hours.  PRG4 concentrations were determined as 219 
described above. 220 
 221 
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HAS1 content: OA synoviocytes were seeded and treated as described for -SMA and 222 
procollagen type I.  HAS1 content in protein isolates were determined using an ELISA 223 
(MyBioSource, USA).  A total of 1μg total protein in 100μL volume was added to the wells 224 
of the ELISA plate.  HAS1 concentrations (ng/mL) were divided by 10 and expressed as 225 
HAS1 content (ng) per μg total protein.  226 
 227 
HAS1 knockdown and its impact on forskolin-induced HA secretion in OA synoviocytes 228 
 229 
OA synoviocytes (300,000 cells per well) in Opti-MEM reduced serum medium (Thermo 230 
Fisher Scientific) were treated with a HAS1 small interfering RNA (siRNA) (Thermo Fisher 231 
Scientific) (25 pmoles per well) or a non-targeted negative control (NC) siRNA (25 pmoles 232 
per well) (Thermo Fisher Scientific) for 48 hours.  Transfection was performed using 233 
Lipofectamine RNAiMAX (Thermo Fisher Scientific) per manufacturer’s recommendations.  234 
To confirm HAS1 knockdown, HAS1 expression was determined as described above.  In a 235 
separate set of experiments, HAS1 knockdown in OA synoviocytes was performed followed 236 
by media change to serum-free DMEM and stimulation with TGF-β1 (1ng/mL) ± forskolin 237 
(10μM) for 24 hours.  Subsequently, HA concentrations were determined in media 238 
supernatants as described above. 239 
      240 
Gene expression studies in Prg4
+/+
 and Prg4
-/-
 synovial tissues and immunocytostaining 241 
of murine synoviocytes  242 
 243 
The phenotype of the Prg4
-/-
 mouse has been previously reported (37), and is characterized 244 
by cartilage degeneration and a hyperplastic synovium contributing to joint failure (37).  The 245 
Prg4
-/- 
and Prg4
+/+
 mouse colonies are maintained by Dr. Jay at Rhode Island Hospital.  246 
Prg4
-/-
 mouse is also commercially available (stock #025737; The Jackson Laboratory, 247 
Maine, USA).  Synovial tissues were isolated from male Prg4
-/- 
 and Prg4
+/+
 mice (8-10 248 
weeks old).  The skin and surrounding tissues of the knee joints were removed.  The joint 249 
capsule was cut open along both sides of the patella under a stereo microscope and the 250 
synovium from the lateral and medial sides was carefully isolated.  A total of 15 Prg4
+/+ 
and 251 
15 Prg4
-/- 
mice were used in this study.   Synovial tissues were harvested from every mouse 252 
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and tissues from 3 mice were randomly pooled into one sample, generating 5 pooled samples 253 
in each genotype.  RNA isolation, cDNA synthesis and qPCR were performed as previously 254 
described (53).  Genes of interest included ACTA2, COL1A1, TIMP-1 and PLOD2 with 255 
GAPDH as an internal reference gene (Thermo Fisher Scientific).  256 
 257 
Prg4
+/+
 and Prg4
-/- 
synoviocytes were isolated as previously described (2).  Synovial tissues 258 
from male Prg4
+/+
 and Prg4
-/-
 mice (15 animals per genotype) were used to isolate the 259 
synoviocytes.  Synoviocytes were plated onto sterile chamber slides (Thermo Fisher 260 
Scientific) at a density of 1.0 x 10
6
 cells per well and allowed to adhere for 24 hrs. 261 
Synoviocytes were incubated with human synoviocyte PRG4 (100 μg/mL) in serum-free 262 
DMEM for 24 hours followed by washing with PBS and cell fixation with 4% formalin.  263 
Probing was performed using anti--SMA antibody (1:100 dilution; ab5694) or anti-collagen 264 
type I antibody (1:200 dilution; ab34710) (Abcam) at 4
o
C overnight.  Following washing 265 
with PBS, cells were incubated with Cy3 goat anti-rabbit IgG antibody (1:200 dilution; 266 
A10520; Thermo Fisher Scientific) for 1 hr at room temperature in the dark.  Following 267 
washing with PBS, Alexa Fluor 488-conjugated phalloidin, a filamentous actin (F-actin) 268 
probe (1:125 dilution; A12379; Thermo Fisher Scientific), was added for 20 min in the dark.   269 
Cells were subsequently mounted with DAPI mounting medium (Vector Labs) and viewed 270 
under a fluorescent microscope (Nikon E 800). 271 
 272 
Basal and TGF-β1 induced OA synoviocytes proliferation and migration  273 
 274 
In sterile 96 well plates, OA synoviocytes (10,000 cells per well) were cultured in serum-free 275 
DMEM media and incubated with forskolin (3, 10 and 30M) ± TGF-β1 (1ng/mL) for 48 276 
hours at 37
o
C.  Cell proliferation was determined using the MTT reagent (Sigma).  OA 277 
synoviocytes (100,000 cells per well) were seeded in 24-well culture plates in DMEM+10% 278 
FBS for 72 hours.  A 1,000 L pipette tip was used to perform a scratch in the confluent 279 
synoviocyte monolayer.  TGF-β1 (1ng/mL) stimulation was performed in serum-free DMEM 280 
± forskolin (10M) for 48 hours.  Subsequently, media was aspirated and cells were stained 281 
(Cell Biolabs, USA) followed by imaging using all-in-one fluorescence microscope 282 
(Keyence, USA).  A region of interest (ROI) was defined and the scratch width was 283 
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measured at multiple locations in the ROI.  The mean scratch width was calculated and used 284 
to estimate the mean scratch area.  Data is presented as the ratio of the scratch areas of the 285 
different experimental groups to the scratch area at baseline.   286 
 287 
 288 
Statistical Analyses 289 
 290 
Variables were initially tested for normality.  Normally distributed variables were compared 291 
using Student’s t-test for two groups or analysis of variance (ANOVA) with Tukey’s post-292 
hoc test for more than two groups.  Variables that did not satisfy the normality assumption 293 
were tested using ANOVA on the ranks.  Statistical analysis of gene expression data was 294 
performed using Ct values (Ct target gene-Ct GAPDH) for each gene of interest.  295 
Significance level was set at 0.05.  296 
 297 
RESULTS 298 
 299 
Forskolin treatment increased intracellular cAMP, reduced ACTA2, COL1A1, TIMP-1 300 
expression and reduced -SMA and procollagen type I in TGF-β1 stimulated OA 301 
synoviocytes  302 
 303 
A representative dose-response of forskolin is shown in figure 1A.  Treatment with forskolin 304 
(0.01μM) did not increase intracellular cAMP while the 0.1, 1 and 10μM forskolin treatments 305 
resulted in detectable increases in cAMP.  Forskolin (10μM) increased intracellular cAMP 306 
compared to vehicle (fig. 1B; p<0.001) (n=3 patients).  TGF-β1 induced ACTA2, COL1A1, 307 
TIMP-1 and PLOD2 expression (fig. 1C through F; p<0.001 versus control for the 4 genes) 308 
(n=4 patients).  Forskolin treatment reduced ACTA2 (fig. 1C; p<0.001), COL1A1 (fig. 1D; 309 
p<0.01), and TIMP-1 (fig. 1E; p<0.001) expression compared to TGF-β1 alone.  Forskolin 310 
treatment did not alter TGF-β1 stimulated PLOD2 expression (fig. 1F; p=0.833).  Forskolin 311 
did not alter basal COL1A1 (p=0.623), TIMP-1 (p=0.802) or PLOD2 (p=0.752) expression.  312 
In contrast, forskolin reduced basal ACTA2 expression (p=0.018).  313 
 314 
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A Western Blot and semi-quantitative analysis of α-SMA using GAPDH as a loading control 315 
are shown in fig. 1G and fig. 1H, respectively.  TGF-β1 increased α-SMA protein in OA 316 
synoviocytes compared to control (fig. 1H; p<0.001) (n=6 patients).  Forskolin reduced 317 
TGF-β1 stimulated α-SMA production (p=0.013).  Forskolin alone did not alter basal α-318 
SMA content (p=0.660).  Representative confocal images of TGF-β1-treated OA 319 
synoviocytes  forskolin is shown in figure 1J.  Control OA synoviocytes exhibited a 320 
positive α-SMA staining, and the appearance of a myofibroblast-like phenotype in a number 321 
of cells.  TGF-β1 treatment resulted in stronger α-SMA staining and the appearance of 322 
myofibrils and this was markedly reduced with forskolin co-treatment.  TGF-β1 increased 323 
procollagen type I protein compared to control (fig. 1I; p<0.01) (n=3 patients).  Forskolin 324 
reduced TGF-β1 linked procollagen type I production (p=0.015), and did not alter basal 325 
procollagen type I (p=0.991).  326 
 327 
Forskolin treatment enhanced HA secretion and modulated HAS isoform gene 328 
expression and HAS1 knockdown attenuated forskolin’s effect on HA production in 329 
TGF-β1 stimulated OA synoviocytes 330 
 331 
HA concentrations were higher in TGF-β1 treated OA synoviocytes and forskolin-treated OA 332 
synoviocytes compared to untreated controls (fig. 2A; p<0.001 for both comparisons) (n=4 333 
patients).  HA concentrations in the TGF-β1 + forskolin group were higher than HA 334 
concentrations in the TGF-β1 or forskolin alone groups (p<0.001 for both comparisons).  335 
TGF-β1 induced HAS1 (fig. 2B; p<0.001) and HAS2 (fig. 2C; p<0.001) with no effect on 336 
HAS3 (fig. 2D; p=0.719) expression in OA synoviocytes (n=4 patients).  Forskolin treatment 337 
upregulated basal HAS1, HAS2 and HAS3 expression (p<0.001 for all comparisons).  338 
Combined treatment of TGF-β1 and forskolin increased HAS1 expression over TGF-β1 alone 339 
(fig. 2B; p=0.026).  In contrast, HAS2 expression in the TGF-β1 + forskolin group was lower 340 
than HAS2 expression in the TGF-β1 group (fig. 2C; p=0.024).  341 
 342 
The total cellular HAS1 content was higher in TGF-β1 (p=0.021) and TGF-β1 + forskolin 343 
(p<0.01) treatments compared to control (fig. 2E) (n=4 patients).  HAS1 content was not 344 
different between TGF-β1 + forskolin and TGF-β1 alone groups (p=0.971).  Similarly, there 345 
was no difference in HAS1 between forskolin and control groups (p=0.303).  HAS1 346 
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expression was reduced by approximately 68% in OA synoviocytes transfected with HAS1 347 
siRNA (fig. 2F; p<0.01) (n=4 OA patients).  HA concentrations in TGF-β1 stimulated HAS1 348 
knockdown OA synoviocytes were not different from unstimulated HAS1 knockdown OA 349 
synoviocytes (fig. 2G; p=0.962) (n=4 patients).  Similarly, HA concentrations in TGF-β1 + 350 
forskolin treated HAS1 knockdown OA synoviocytes were not different from HA 351 
concentrations in TGF-β1 treated HAS1 knockdown OA synoviocytes (p=0.514).  Finally, 352 
HA concentrations in TGF-β1 + forskolin treated OA synoviocytes were higher than HA 353 
concentrations in TGF-β1 + forskolin treated HAS1 knockdown OA synoviocytes (p<0.001).    354 
 355 
Forskolin treatment enhanced PRG4 expression and secretion in TGF-β1 stimulated 356 
OA synoviocytes 357 
 358 
TGF-β1 induced PRG4 expression (fig. 3A; p<0.001) and increased PRG4 production by OA 359 
synoviocytes (fig. 3B; p<0.01) (n=4 patients).  Forskolin did not alter basal PRG4 expression 360 
(fig. 3A; p=0.063) or PRG4 production (fig. 3B; p=0.996) in OA synoviocytes.  PRG4 361 
expression in the TGF-β1 + forskolin group was higher than TGF-β1 alone (fig. 3A; 362 
p=0.037).  Correspondingly, PRG4 concentrations were higher in the TGF-β1 + forskolin 363 
group compared to the TGF-β1 group (fig. 3B; p=0.031).   364 
 365 
Impact of PRG4 and HA treatments on ACTA2 and COL1A1 expression and -SMA 366 
and procollagen type I in TGF-β1 stimulated OA synoviocytes 367 
 368 
ACTA2 expression was lower in the TGF-β1 + PRG4 group compared to TGF-β1 alone (fig. 369 
3C; p<0.001) (n=4 patients).  Similarly, ACTA2 expression in the TGF-β1+ HA and TGF-β 1 370 
+ PRG4 + HA groups was lower than ACTA2 expression in TGF-β1 alone (p<0.001 for both 371 
comparisons).  COL1A1 expression was lower in the TGF-β1 + PRG4 group compared to 372 
TGF-β1 + HA (p<0.01) or TGF-β1 alone (p<0.001) (fig. 3D) (n=4 OA patients).  In contrast, 373 
HA treatment did not alter TGF-β1 induced COL1A1 expression (p=0.897).  COL1A1 374 
expression in the TGF-β1 + PRG4 + HA group was lower than TGF-β1 (p<0.001) and TGF- 375 
β1 + HA (p<0.01) groups. 376 
 377 
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A Western Blot and semi-quantitative analysis of α-SMA using GAPDH as a loading control 378 
are shown in 3E and 3F, respectively.  α-SMA content was lower in TGF-β1 + PRG4 (fig. 379 
3F; p<0.01) and in TGF-β1 + HA (p<0.01) compared to TGF-β1 alone (n=4 patients).  380 
Procollagen type I content was lower in TGF-β1 + PRG4 compared to TGF-ß1 alone (fig. 381 
3G; p<0.01) (n=4 patients).  There was no difference in procollagen type I content between 382 
TGF-β1 + HA and TGF-β1 groups (p=0.059). 383 
 384 
A cell permeable cAMP analog treatment reduced ACTA2 and COL1A1 expression and 385 
enhanced HA and PRG4 secretion in TGF-β1 stimulated OA synoviocytes 386 
 387 
TGF-β1 induced ACTA2 and COL1A1 expression in OA synoviocytes (fig. 4A and 4B; 388 
p<0.001 against control for both genes).  8-bromo cAMP (100M) treatment did not 389 
significantly alter TGF-β1 induced ACTA2 and COL1A1 expression (p>0.05 for both 390 
comparisons).  In contrast, 8-bromo cAMP (500M) treatment reduced ACTA2 (p<0.001) 391 
and COL1A1 (p<0.001) expression in TGF-β1 stimulated OA synoviocytes (n=3 OA 392 
patients).  HA and PRG4 media concentrations in TGF-β1 + 8-bromo cAMP (500M) group 393 
were significantly higher than corresponding concentrations in TGF-β1 only group (fig. 4C 394 
and 4D; p<0.001 for both comparisons) (n=3 OA patients).  395 
 396 
ACTA2, COL1A1 and TIMP-1 expression was higher in Prg4
-/- 
synovial tissues and 397 
human synoviocyte PRG4 treatment reduced α-SMA and collagen type I staining in 398 
Prg4
-/- 
synoviocytes 399 
   400 
Expression of ACTA2 (p=0.021), COL1A1 (p<0.001) and TIMP-1 (p<0.01) was higher in 401 
Prg4
-/-
 synovia compared to Prg4
+/+
 synovia (fig. 5A).  In contrast, PLOD2 expression was 402 
lower in Prg4
-/-
 tissues compared to Prg4
+/+
 tissues (p<0.01). 403 
 404 
Merged images of α-SMA and collagen type I stained Prg4
+/+
 and Prg4
-/-
 synoviocytes is 405 
shown in figure 5B.  We observed strong α-SMA and collagen type I staining in Prg4
-/-
 406 
synoviocytes.  α-SMA staining co-localized with F-actin staining.    In contrast, there was no 407 
detected α-SMA or collagen type I staining in Prg4
+/+
 synoviocytes.  PRG4 treatment 408 
reduced α-SMA and collagen type I staining in Prg4
-/-
 synoviocytes. 409 
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 410 
Forskolin reduced TGF-β1 induced OA synoviocyte proliferation and migration  411 
 412 
Forskolin (3 M and 10M) treatments did not alter basal OA synoviocyte proliferation (fig. 413 
6A; p=0.891 and p=0.117)  (n=4 patients).  In contrast, the 30M treatment increased basal 414 
OA synoviocyte proliferation compared to untreated control (p<0.01).  TGF-β1 stimulated 415 
OA synoviocyte proliferation (fig. 6B; p<0.001) (n=4 patients).  OA synoviocyte 416 
proliferation in the TGF-β1 + forskolin (30M) group was lower than TGF-β1 alone 417 
(p<0.001), TGF-β1 + forskolin (3M) (p<0.01) or TGF-β1 + forskolin (10M) (p<0.01).  418 
There was no difference in cell proliferation between TGF-β1 + forskolin (10M) and TGF-419 
β1 alone (p=0.063).  Representative wound scratch images are show in figure 6C.  TGF-β1 420 
enhanced OA synoviocyte migration (fig. 6D; p<0.01) (n=4 patients).  OA synoviocyte 421 
migration in the TGF-β1 + forskolin (10M) group was lower than in the TGF-β1 only group 422 
(p<0.01).  There was no difference in cell migration between forskolin treated and untreated 423 
OA synoviocytes (p=0.887). 424 
 425 
DISCUSSION 426 
 427 
In this paper, we show that TGF- β1 resulted in excess collagen type I production, induction 428 
of TIMP-1 and PLOD2 expression and -SMA upregulation, together with stimulating OA 429 
synoviocyte migration and proliferation.  Forskolin, by virtue of its ability to generate cAMP, 430 
reduced collagen production and blunted TIMP-1 expression while inhibiting synoviocyte 431 
proliferation and migration.  PLOD2 induction in osteoarthritic synoviocytes is consistent 432 
with its established role in mediating synovial collagen crosslinking (3, 29).  Forskolin did 433 
not alter PLOD2 expression, which may be related to the TGF-β1’s signaling pathways.  434 
Remst et al have shown that in OA synoviocytes, an ALK 1/2/3/6 inhibitor completely 435 
blocked TGF-β1 induced collagen type I expression whereas TGF-β1 induced PLOD2 436 
expression was only slightly reduced (34). 437 
 438 
OA synoviocytes proliferate in response to various mitogenic stimuli (1, 5, 15).  In our 439 
experiments, TGF-β1 induced cell proliferation with a magnitude comparable to what has 440 
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been previously reported (5).  Forskolin, at the treatment level that inhibited migration, 441 
exhibited a marginal antiproliferative effect and a higher concentration was needed to 442 
observe significant antagonism of TGF-β1’s mitogenic effect.  This might be due to a low 443 
proliferative capacity of OA synoviocytes.  In the absence of TGF-β1, forskolin acted as a 444 
mitogen to produce a low, yet significant, stimulation of proliferation.  Forskolin directly 445 
binds to AC and generates cAMP from ATP (43).  The increase in cAMP results in activation 446 
of protein kinase A (PKA) dependent and independent pathways (39, 43).  In the presence of 447 
growth factors, forskolin activates cAMP-dependent PKA which interferes with Raf-1 448 
activation and signaling to blunt cell proliferation (11).  PKA also activates CREB, which 449 
can compete for cofactors with SMAD-mediated transcription stimulated by TGF-β1 (22). In 450 
the absence of growth factor, PKA-dependent and independent pathways stimulate cAMP-451 
mediated cell proliferation (6).   452 
 453 
We measured -SMA in OA synoviocytes from human patients and forskolin addition 454 
consistently attenuated TGF-β1-stimulated -SMA expression.  -SMA is a specific marker 455 
of myofibroblasts (7, 8).  Myofibroblasts are effector cells in fibrosis that possess enhanced 456 
ability to produce collagen, proliferate and migrate (7, 8).  We have shown that forskolin 457 
treatment appeared to markedly reduce TGF-β1’s induced myofibroblast-like phenotype in 458 
OA synoviocytes.  The causal role that myofibroblasts may play in synovial fibrosis is 459 
understudied and unclear.  Steenvoorden et al reported that -SMA staining was only found 460 
in blood vessels in synovia from healthy individuals (49).  Interestingly, TGF- β1 stimulation 461 
of normal synoviocytes increased collagen type I expression with no effect on -SMA 462 
expression or production (49).  Mattey et al have shown that TGF-β1 or IL-4 treatments 463 
trigger differentiation of OA synoviocytes into myofibroblast-like cells, characterized by -464 
SMA expression in vitro (28).  Evidence relating myofibroblasts to changes occurring in joint 465 
fibrosis was reported by Sasabe et al (40).  Using a rat knee contracture model, 466 
myofibroblasts expressing -SMA were detected as early as 1 week from joint 467 
immobilization and this was associated with increased collagen type I expression and joint 468 
capsule fibrosis (40).  We have also detected -SMA protein in Prg4
-/-
 synoviocytes with no 469 
-SMA signal in normal murine synoviocytes.  The positive -SMA signal in Prg4
-/-
 470 
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knockout synoviocytes is associated with phenotypical changes in the synovium including 471 
synovial lining thickening and enhanced synoviocyte proliferation (37). 472 
 473 
TGF-β1 induced HAS1 and HAS2 expression with no effect on HAS3, and enhanced HA 474 
secretion by OA synoviocytes.  Synoviocytes contain higher levels of HAS1 message 475 
compared to HAS2 with HAS3 being the least abundant (33).  Earlier reports are in agreement 476 
with our finding that TGF-β1 stimulation of arthritic synoviocytes resulted in a higher 477 
HAS1/HAS2 transcript ratio above control level and that in turn resulted in higher 478 
extracellular HA levels (5, 33).  Our data suggests that the majority of TGF-β1 linked HA 479 
secretion is mediated by HAS1, as HAS1 knockdown diminished extracellular HA 480 
concentrations.  Co-treatment with forskolin increased the HAS1/HAS2 transcript ratio 481 
above the corresponding TGF-ß1 ratio with greater HA secretion over 24 hours.  The 482 
increase in HAS1 mRNA in forskolin-treated synoviocytes did not translate to increased 483 
HAS1 cellular pool.  This might be related to the rate at which the message is being 484 
translated.  Furthermore, the majority of HAS1 cellular fraction is inactive and is found in the 485 
cytoplasm either diffused or partially co-localized with the Golgi apparatus, whereas the 486 
plasma membrane-bound fraction is small and is catalytically active (51).  Therefore, the 487 
possibility that the newly synthesized HAS1 enzyme, in response to forskolin treatment, 488 
could have been trafficked to the membrane resulting in increasing the rate of HA synthesis 489 
could not be ruled out.  Assessing the impact of forskolin on membrane-bound HAS1 level 490 
and activity was technically challenging and was not feasible to perform.  Our data should 491 
also be considered in the context that other factors e.g. post-translational modifications, 492 
availability of precursors and regulation of HAS activity will likely contribute to the amount 493 
of HA secreted by the OA synoviocytes (33). 494 
 495 
Increasing intracellular cAMP resulted in increasing PRG4 expression and production by OA 496 
synoviocytes in the setting of TGF-1 stimulation.  This contextual effect is due to CREB 497 
stimulation which was previously shown to enhance PRG4 production by superficial zone 498 
articular chondrocytes (31).  PRG4 is a mucin-like glycoprotein synthesized by synoviocytes 499 
and superficial zone articular chondrocytes with a heavily glycosylated central domain and 500 
an N- and C-termini (19).  The mouse Prg4 gene is highly homologous to the human Prg4 501 
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gene (14).  Human and mouse Prg4 genes each consist of 12 exons and the N- and C-termini 502 
are highly conserved across species (14).   PRG4 exists in the synovial fluid in monomeric or 503 
multimeric forms and functions as a boundary lubricant (19, 42).  PRG4 binds to CD44, the 504 
HA receptor, and exerts an anti-inflammatory effect in OA synoviocytes (1, 2).  PRG4 also 505 
acts in an autocrine manner to regulate OA synoviocyte proliferation (1).  We have found 506 
that PRG4 and HA had equivalent efficacy in reducing -SMA content in osteoarthritis 507 
synoviocytes.  However, PRG4, at a physiologically-relevant concentration (20), was more 508 
efficacious than HA in reducing collagen I expression and production, indicative of a 509 
potential role in antagonizing profibrotic alterations in synovial tissues.  This function is 510 
likely related to its interaction with the CD44 receptor, given that HA reduced synovial 511 
fibrosis in a CD44-mediated manner (32).  PRG4 reduced collagen I and -SMA staining in 512 
Prg4
-/-
 synoviocytes.  The link between PRG4 expression and synovial fibrosis is further 513 
illustrated by the upregulation of collagen type I, TIMP-1 and -SMA in the Prg4
-/- 
514 
synovium.  As laying excess collagen type I is a prominent feature in synovial fibrosis, the 515 
strong immunocytostaining for collagen type I in Prg4
-/-
 synoviocytes, coupled with other 516 
synovial changes, support a fibrotic Prg4
-/- 
synovium.  We did not include human normal 517 
synoviocytes in our study design.  Furthermore, we did not examine the efficacy of forskolin 518 
or PRG4 in an in-vivo model of synovial fibrosis.   519 
 520 
In summary, our data demonstrate that forskolin; a diterpene produced by the roots of the 521 
Indian plant Coleus forskohili (43), increases intracellular cAMP levels and produces an 522 
antifibrotic effect in OA synoviocytes.  Increasing intracellular cAMP levels directly via 523 
treatment with a cell permeable cAMP analog recapitulated the antifibrotic effect of 524 
forskolin.  Forskolin reduces collagen type I expression and procollagen type I production 525 
and inhibits TGF-β1 linked fibroblast migration and proliferation.  Forskolin also increased 526 
HA and PRG4 secretion by OA synoviocytes; an effect that may contribute to its overall 527 
antifibrotic efficacy. Approaches that increase cAMP levels in synoviocytes can promote an 528 
antifibrotic phenotype and may be a novel approach for slowing the progression of synovial 529 
fibrosis in OA. 530 
 531 
 532 
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LIST OF ABBREVIATIONS 533 
-SMA: Alpha smooth muscle actin; AC: Adenylyl cyclase; ACTA2: Alpha smooth muscle 534 
actin gene; ALK: Anaplastic Lymphoma Kinase; ANOVA: Analysis of variance; cAMP: 535 
Cyclic adenosine monophosphate; cDNA: Complementary deoxyribonucleic acid; CD44: 536 
Cluster of differentiation 44; COL1A1: Collagen type I gene; Ct: Threshold cycle; DMEM: 537 
Dulbecco’s Modified Eagle’s Medium; DPBS: Dulbecco’s Phosphate-Buffered Saline; 538 
ELISA: Enzyme linked immunosorbent assay; FITC: Fluorescein Isothiocyanate; FsK: 539 
Forskolin; GAPDH: Glyceraldehyde-3-Phosphate Dehydrogenase; GPCR: G-protein 540 
coupled receptor; HA: Hyaluronan; HAS: Hyaluronan synthase; IACUC: Institutional 541 
Animal Care and Use Committee; kDa: Kilodaltons; MTT: 3-(4,5-Dimethylthiazol-2-Yl)-542 
2,5-Diphenyltetrazolium Bromide; MW: Molecular Weight; OA: Osteoarthritis; PAGE: 543 
Polyacrylamide Gel Electrophoresis; PKA: Protein kinase A; PLOD2: Procollagen-lysine, 544 
2-oxoglutarate 5-dioxygenase 2; PRG4: Proteoglycan-4; qPCR: Quantitative polymerase 545 
chain reaction; RNA: Ribonucleic Acid; ROI: Region of interest; S.D.: Standard deviation; 546 
siRNA: Small interfering ribonucleic acid; TBS-T: Tris buffered saline + 0.05% Tween 20; 547 
TGF-1: Transforming growth factor beta-1; TIMP-1: Tissue Inhibitor of Metalloproteinase 548 
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Legends 858 
 859 
Fig. 1 Impact of forskolin (FsK) treatment on intracellular cyclic adenosine monophosphate 860 
(cAMP) levels, basal and transforming growth factor beta 1 (TGF-β1)-induced alpha smooth 861 
muscle actin (ACTA2), collagen I (COL1A1), tissue inhibitor of metalloproteinase 1 (TIMP-862 
1) and procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2) gene expression and 863 
alpha smooth muscle action (-SMA) and procollagen type I production in osteoarthritic 864 
(OA) synoviocytes.  TGF-β1 (1ng/ml) stimulation of OA-FLS was performed for 24 hours in 865 
all experiments except -SMA immunocytostaining (stimulation was performed using 1 866 
ng/ml TGF-β1 for 48 hours). Data is presented as the mean  S.D. of experiments utilizing 867 
OA synoviocytes from different patients.  *p<0.001; **p<0.01; ***p<0.05.   868 
 869 
A.  Representative dynamic change in intracellular cAMP levels in OA synoviocytes 870 
following treatment with FsK (0.01, 0.1, 1 and 10μM).  FsK treatment (0.1, 1 and 10μM) 871 
resulted in detectable cAMP levels in OA synoviocytes.  The cAMP signal was detected 872 
using a cAMP-specific sensor.  B. cAMP levels were elevated in FsK (10μM)-treated OA 873 
synoviocytes (n=3 patients). C.  FsK treatment (1 and 10μM) reduced TGF-β1 induced 874 
ACTA2 expression (n=4 patients). D.  FsK treatment (10μM) reduced TGF-β1 induced 875 
COL1A1 expression (n=4 patients). E.  FsK treatment (10μM) reduced TGF-β1 induced 876 
TIMP-1 expression (n=4 patients).  F.  Fsk treatment (10M) did not alter TGF-β1 induced 877 
PLOD2 expression (n=4 patients).  G.  Western Blot of α-SMA (predicted MW: 42 kDa) in 878 
control, TGF-β1, TGF-β1 + FsK and FsK-treated OA synoviocytes.  GAPDH (predicted 879 
MW: 40 kDa) was used as loading control.  H. Semi-quantitative densitometry analysis of α-880 
SMA normalized to GAPDH and expressed as ratio to control in cell extracts of control, 881 
TGF-β1, TGF-β1 + FsK and FsK-treated OA synoviocytes.  FsK (10μM) treatment reduced 882 
TGF-β1 linked increase in α-SMA in OA synoviocytes (n=6 patients).  I.  Procollagen type I 883 
content in cell extracts of control, TGF-β1, TGF-β1 + FsK and FsK-treated OA synoviocytes.  884 
Data was normalized to total protein content.  FsK (10μM) treatment reduced TGF-β1 linked 885 
increase in procollagen type I content in OA synoviocytes (n=3 patients).  J. FsK (10μM) 886 
treatment reduced α-SMA staining and myofibroblast-like phenotype in TGF-β1 stimulated 887 
OA synoviocytes.  888 
 889 
Fig. 2 Impact of forskolin (FsK; 10μM) treatment on basal and transforming growth factor 890 
beta 1 (TGF-β1)-induced hyaluronan (HA) production, expression of hyaluronan synthase 891 
isoforms 1, 2, and 3 (HAS1, HAS2 and HAS3) and the role of HAS1 in mediating TGF-β1 892 
and FsK-linked HA production in osteoarthritic (OA) synoviocytes.  Data is presented as the 893 
mean  S.D. of experiments utilizing OA synoviocytes from 4 patients.  *p<0.001; 894 
**p<0.01; ***p<0.05; n.s.: non significant.    895 
 896 
A. Hyaluronan concentrations in control, TGF-β1, TGF-β1 + FsK, and FsK-treated OA 897 
synoviocytes. B. FsK treatment enhanced TGF-β1 induced HAS1 expression.  C. FsK 898 
treatment reduced TGF-β1 induced HAS2 expression.  D. FsK treatment increased basal 899 
HAS3 expression in OA synoviocytes.  E. HAS1 protein content in cell extracts of control, 900 
TGF-β1, TGF-β1 + FsK and FsK-treated OA synoviocytes.  Data was normalized to total 901 
protein content.  There was no difference in HAS1 protein between TGF-β1 and TGF-β1 + 902 
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FsK treatments. F.  HAS1 expression was reduced in HAS1 siRNA-treated OA synoviocytes 903 
compared to untreated control and negative control siRNA (NC siRNA)-treated OA 904 
synoviocytes.  G. FsK and/or TGF-β1 treatments did not significantly change hyaluronan 905 
production following HAS1 knockdown in OA synoviocytes.  906 
 907 
Fig. 3 Impact of forskolin (FsK; 10μM) treatment on basal and transforming growth factor 908 
beta 1 (TGF-β1) induced proteoglycan-4 (PRG4) gene expression and production by 909 
osteoarthritic (OA) synoviocytes and efficacy of human synoviocyte PRG4 (100g/ml) and 910 
hyaluronan (HA) (100g/ml) in modulating TGF-β1 induced expression and production of 911 
alpha smooth muscle actin and collagen type I in OA synoviocytes.  Data is presented as the 912 
mean  S.D. of experiments utilizing OA synoviocytes from 4 patients.   *p<0.001; 913 
**p<0.01; ***p<0.05.   914 
 915 
A.  TGF-β1 increased PRG4 expression and FsK treatment enhanced TGF-ß1’s effect.  B. 916 
FsK treatment enhanced TGF-β1 linked PRG4 production by OA synoviocytes.  C. PRG4 917 
and/or HA treatments reduced TGF-β1 induced alpha smooth muscle actin gene (ACTA2) 918 
expression in OA synoviocytes.  D.  PRG4 treatment reduced TGF-β1 induced collagen type 919 
I (COL1A1) gene expression in OA synoviocytes.  E. Western Blot of α-SMA (predicted 920 
MW: 42 kDa) in control, TGF-β1, TGF-β1 + PRG4 (100g/ml) and TGF-β1 + HA 921 
(100g/ml) treated OA synoviocytes.  GAPDH (predicted MW: 40 kDa) was used as loading 922 
control.  F. Semi-quantitative densitometry analysis of α-SMA normalized to GAPDH and 923 
expressed as ratio to control in cell extracts of control, TGF-β1, TGF-β1 + PRG4 and TGF-924 
β1 + HA treated OA synoviocytes.  PRG4 and HA treatments reduced TGF-β1 linked 925 
increase in α-SMA in OA synoviocytes.  G. Procollagen type I content in cell extracts of 926 
control, TGF-β1, TGF-β1 + PRG4 and TGF-β1 + HA-treated OA synoviocytes.  Data was 927 
normalized to total protein content.  PRG4 treatment reduced TGF-β1 linked increase in 928 
procollagen type I content in OA synoviocytes.             929 
    930 
Fig. 4 Impact of 8-bromo cAMP (8-Br-cAMP; 100 and 500M) treatment on basal and 931 
transforming growth factor beta 1 (TGF-1)-induced alpha smooth muscle actin (ACTA2) 932 
and collagen I (COL1A1) expression and hyaluronan (HA) and proteoglycan-4 (PRG4) 933 
secretion in osteoarthritic synoviocytes.  Data is presented as the mean  S.D. of experiments 934 
utilizing OA synoviocytes from 3 patients.  *p<0.001.  A. 8-Br-cAMP (500M) reduced 935 
TGF-β1 linked ACTA2 expression in OA synoviocytes.  B.  8-Br-cAMP (500M) reduced 936 
TGF-β1 linked COL1A1 expression in OA synoviocytes.  C.  8-Br-cAMP (500M) increased 937 
HA secretion in TGF- β1stimulated OA synoviocytes.  D.  8-Br-cAMP (500M) increased 938 
PRG4 secretion in TGF- β1stimulated OA synoviocytes.   939 
   940 
Fig. 5 Gene expression of alpha smooth muscle actin (ACTA2), collagen type I (COL1A1), 941 
tissue-inhibitor of metalloproteinase-1 (TIMP-1) and procollagen-lysine, 2-oxoglutarate 5-942 
dioxygenase 2 (PLOD2) in synovial tissues isolated from Prg4
+/+
 and Prg
-/-
 mice and 943 
immunocytostaining of alpha smooth muscle actin (-SMA) and collagen type I in Prg
+/+ 
944 
and Prg4
-/- 
synoviocytes and impact of human synoviocyte PRG4 treatment.  *p<0.001; 945 
**p<0.01; ***p<0.05. 946 
 947 
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A. ACTA2, COL1A1 and TIMP-1 expression in Prg4
-/-
 synovial tissues was higher than 948 
Prg4
+/+
 synovial tissues.  PLOD2 expression in Prg4
-/- 
synovial tissues was lower than 949 
Prg4
+/+ 
synovial tissues.  Each group contained 5 samples with each sample generated by 950 
pooling synovial tissues from 3 mice.  951 
 952 
B. Merged images depicting -SMA and collagen type I protein immunostaining in isolated 953 
Prg4
+/+
 synoviocytes and Prg4
-/-
 synoviocytes (bright orange) and counterstained with F-954 
actin (green) and DAPI (blue).  -SMA and collagen type I staining was detected in Prg4
-/-
 955 
synoviocytes (white arrows) and no staining was detected in Prg4
+/+
 synoviocytes.  -SMA 956 
and collagen type I staining intensities were reduced by human synoviocyte PRG4 treatment 957 
for 24 hours.  Scale = 50m.    958 
 959 
Fig. 6 Impact of forskolin (FsK) treatment on basal and transforming growth factor beta 1 960 
(TGF-β1) induced proliferation and migration of osteoarthritic (OA) synoviocytes.  Data is 961 
presented as the mean  S.D. of experiments utilizing OA synoviocytes from 4 patients.  962 
*p<0.001; **p<0.01; ***p<0.05.  Scale = 1,000 μM.  A.   FsK (30μM) treatment enhanced 963 
basal OA synoviocyte proliferation.  B.  FsK (30μM) treatment reduced TGF-β1-induced OA 964 
synoviocyte proliferation. C.  Representative images showing baseline and 48-hour basal, 965 
TGF-β1, TGF-β1 + FsK and FsK alone induced OA synoviocyte migration using an in vitro 966 
scratch assay.  D. FSK (10μM) treatment reduced TGF-β1 stimulated OA synoviocyte 967 
migration.  968 






